{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:45:37Z","timestamp":1776872737406,"version":"3.51.2"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100003157","name":"Myasthenia Gravis Foundation of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003157","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.expneurol.2019.113146","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T12:41:20Z","timestamp":1576154480000},"page":"113146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Inhibition of the transcription factor ROR-\u03b3 reduces pathogenic Th17 cells in acetylcholine receptor antibody positive myasthenia gravis"],"prefix":"10.1016","volume":"325","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-2437","authenticated-orcid":false,"given":"John S.","family":"Yi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa A.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti","family":"Raja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice M.","family":"Massey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vern C.","family":"Juel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa D.","family":"Hobson-Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karissa","family":"Gable","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey T.","family":"Guptill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2019.113146_bb0005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cyto.2017.05.008","article-title":"Ablation of IL-17 expression moderates experimental autoimmune myasthenia gravis disease severity","volume":"96","author":"Aguilo-Seara","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.expneurol.2019.113146_bb0010","unstructured":"BD Biosciences. Generation of human IL-17-producing cells (Th17-like cells) in vitro."},{"key":"10.1016\/j.expneurol.2019.113146_bb0015","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1073\/pnas.0914839107","article-title":"Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties","volume":"107","author":"Billerbeck","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2019.113146_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-015-0092-3","article-title":"A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis","volume":"6","author":"Campa","year":"2016","journal-title":"Dermatol. Ther. (Heidelb.)"},{"key":"10.1016\/j.expneurol.2019.113146_bb0025","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.4049\/jimmunol.1501339","article-title":"Autoreactive T cells from patients with myasthenia gravis are characterized by elevated IL-17, IFN-gamma, and GM-CSF and diminished IL-10 production","volume":"196","author":"Cao","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.expneurol.2019.113146_bb0030","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev-immunol-032712-100019","article-title":"T cell-mediated host immune defenses in the lung","volume":"31","author":"Chen","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.expneurol.2019.113146_bb0035","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.expneurol.2019.113146_bb0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.coph.2014.06.004","article-title":"Th17 plasticity: pathophysiology and treatment of chronic inflammatory disorders","volume":"17","author":"Cosmi","year":"2014","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.expneurol.2019.113146_bb0045","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1749-6632.2012.06791.x","article-title":"Defects of immunoregulatory mechanisms in myasthenia gravis: role of IL-17","volume":"1274","author":"Gradolatto","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.expneurol.2019.113146_bb0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaut.2013.12.015","article-title":"Both Treg cells and Tconv cells are defective in the Myasthenia gravis thymus: roles of IL-17 and TNF-alpha","volume":"52","author":"Gradolatto","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.expneurol.2019.113146_bb0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1021\/mp200305u","article-title":"Carbosilane dendrimer 2G-NN16 represses Tc17 differentiation in primary T CD8+ lymphocytes","volume":"9","author":"Gras","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.expneurol.2019.113146_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188391","article-title":"Pharmacological inhibition of RORgammat suppresses the Th17 pathway and alleviates arthritis in vivo","volume":"12","author":"Guendisch","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2019.113146_bb0065","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.91127","article-title":"Retinoic-acid-orphan-receptor-C inhibition suppresses Th17 cells and induces thymic aberrations","volume":"2","author":"Guntermann","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.expneurol.2019.113146_bb0070","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.celrep.2016.11.073","article-title":"Inhibition of RORgammaT skews TCRalpha gene rearrangement and limits T cell repertoire diversity","volume":"17","author":"Guo","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.expneurol.2019.113146_bb0075","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/mi.2012.128","article-title":"Th17 cells confer long-term adaptive immunity to oral mucosal Candida albicans infections","volume":"6","author":"Hernandez-Santos","year":"2013","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.expneurol.2019.113146_bb0080","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000486037","article-title":"Increased proportion of Tc17 and Th17 cells and their significant reduction after thymectomy may be related to disease progression in myasthenia gravis","volume":"24","author":"Hosseini","year":"2017","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.expneurol.2019.113146_bb0085","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01571-8","article-title":"Transcriptional signature of human pro-inflammatory TH17 cells identifies reduced IL10 gene expression in multiple sclerosis","volume":"8","author":"Hu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.expneurol.2019.113146_bb0090","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/eji.200939412","article-title":"A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity","volume":"39","author":"Huber","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.expneurol.2019.113146_bb0095","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jdermsci.2019.03.002","article-title":"A novel RORgammat inhibitor is a potential therapeutic agent for the topical treatment of psoriasis with low risk of thymic aberrations","volume":"93","author":"Imura","year":"2019","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.expneurol.2019.113146_bb0100","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.expneurol.2019.113146_bb0105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. task force of the medical scientific advisory board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2019.113146_bb0110","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.4049\/jimmunol.0801347","article-title":"Cutting edge: phenotypic characterization and differentiation of human CD8+ T cells producing IL-17","volume":"182","author":"Kondo","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.expneurol.2019.113146_bb0115","doi-asserted-by":"crossref","first-page":"18460","DOI":"10.1073\/pnas.0809850105","article-title":"IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells","volume":"105","author":"Korn","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2019.113146_bb0120","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni.2416","article-title":"Induction and molecular signature of pathogenic TH17 cells","volume":"13","author":"Lee","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.expneurol.2019.113146_bb0125","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2019.113146_bb0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.expneurol.2018.11.006","article-title":"Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients","volume":"312","author":"Li","year":"2019","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2019.113146_bb0135","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1189\/jlb.0207111","article-title":"Induction of a distinct CD8 Tnc17 subset by transforming growth factor-beta and interleukin-6","volume":"82","author":"Liu","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.expneurol.2019.113146_bb0140","doi-asserted-by":"crossref","first-page":"e826","DOI":"10.1111\/j.1365-2567.2009.03089.x","article-title":"Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis","volume":"128","author":"Mu","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.expneurol.2019.113146_bb0145","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.autrev.2013.12.004","article-title":"Th17 and regulatory T cell balance in autoimmune and inflammatory diseases","volume":"13","author":"Noack","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.expneurol.2019.113146_bb0155","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1189\/JLB.0109046","article-title":"IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines","volume":"86","author":"Ortega","year":"2009","journal-title":"J. Leukoc. Biol."},{"issue":"Suppl. 3","key":"10.1016\/j.expneurol.2019.113146_bb0160","doi-asserted-by":"crossref","first-page":"iii26","DOI":"10.1136\/ard.2008.098004","article-title":"Th17 cells in immunity and autoimmunity","volume":"67","author":"Oukka","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.expneurol.2019.113146_bb0165","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2019.113146_bb0170","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mus.22070","article-title":"Increased serum interleukin-17 levels in patients with myasthenia gravis","volume":"44","author":"Roche","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.expneurol.2019.113146_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2016.07.004","article-title":"Post-translational regulation of RORgammat-A therapeutic target for the modulation of interleukin-17-mediated responses in autoimmune diseases","volume":"30","author":"Rutz","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.expneurol.2019.113146_bb0180","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1212\/01.CON.0000455873.30438.9b","article-title":"Myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"20","author":"Sanders","year":"2014","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.expneurol.2019.113146_bb0185","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1196\/annals.1254.057","article-title":"A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score","volume":"998","author":"Sanders","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.expneurol.2019.113146_bb0190","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/eji.201445064","article-title":"IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis","volume":"45","author":"Schaffert","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.expneurol.2019.113146_bb0195","article-title":"Development of a topical treatment for psoriasis targeting RORgamma: from bench to skin","volume":"11","author":"Smith","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2019.113146_bb0200","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.imlet.2016.05.001","article-title":"IL-17+ CD8+ T cells: differentiation, phenotype and role in inflammatory disease","volume":"178","author":"Srenathan","year":"2016","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.expneurol.2019.113146_bb0205","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1002\/eji.200636662","article-title":"Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis","volume":"36","author":"Uyttenhove","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.expneurol.2019.113146_bb0210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.imlet.2019.03.018","article-title":"Effector memory regulatory T cells were most effective at suppressing RANKL but their frequency was downregulated in tibial fracture patients with delayed union","volume":"209","author":"Wang","year":"2019","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.expneurol.2019.113146_bb0215","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cyto.2015.06.011","article-title":"Elevated plasma interleukin-17A in a subgroup of myasthenia gravis patients","volume":"78","author":"Xie","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.expneurol.2019.113146_bb0220","doi-asserted-by":"crossref","DOI":"10.1038\/srep37977","article-title":"Pharmacologic modulation of RORgammat translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritis","volume":"6","author":"Xue","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.expneurol.2019.113146_bb0225","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature07021","article-title":"IL-21 and TGF-beta are required for differentiation of human T(H)17 cells","volume":"454","author":"Yang","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.expneurol.2019.113146_bb0230","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2013.12.005","article-title":"Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis","volume":"52","author":"Yi","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.expneurol.2019.113146_bb0235","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1042\/CS20110496","article-title":"IL-17\/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential","volume":"122","author":"Zhu","year":"2012","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.expneurol.2019.113146_bb0240","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature10957","article-title":"Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta","volume":"484","author":"Zielinski","year":"2012","journal-title":"Nature"}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488619302936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488619302936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:54:55Z","timestamp":1758002095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488619302936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":47,"alternative-id":["S0014488619302936"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2019.113146","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of the transcription factor ROR-\u03b3 reduces pathogenic Th17 cells in acetylcholine receptor antibody positive myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2019.113146","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113146"}}